The coronavirus vaccine being developed by UK’s Oxford is “safe, well-tolerated and immunogenic”. The human trial results of phase one and two of the Oxford University’s coronavirus vaccine showed that the injection led to them making antibodies and white blood cells that can fight Covid-19 infection.
“The phase 1/2 Oxford COVID-19 vaccine trial is now published. The vaccine is safe, well-tolerated, and immunogenic. Congratulations to Pedro Folegatti and colleagues. These results are extremely encouraging,” said Richard Horton, Editor in Chief of UK based medical Journal ‘The Lancet’ that published the results.
The vaccine – called ChAdOx1 nCoV-19 was tested on 1077 people in phase I and II of the human trials. None of the volunteers faced any serious adverse effects due to the vaccine and antibodies were generated to fight the coronavirus.
“Local and systemic reactions were more common in the ChAdOx1 nCoV-19 group and many were reduced by use of prophylactic paracetamol, including pain, feeling feverish, chills, muscle ache, headache,
and malaise. There were no serious adverse events related to ChAdOx1 nCoV-1
“Anti-spike IgG responses rose by day 28 and were boosted following a second dose. Neutralising antibody responses against SARS-CoV-2 were detected in 32 (91 per cent) of 35 participants after a single dose when measured in MNA80 and in 35 (100 per cent) participants when measured in PRNT50.”
“After a booster dose, all participants had neutralising activity (nine of nine in MNA80 at day 42 and ten of ten in Marburg VN on day 56),” the results showed.
The government of UK has already ordered 100 million doses of the vaccine being developed by the Oxford University. While the latest results are highly encouraging, it will be a little early to say that coronavirus now has a cure as phase trials are still underway.